No results for ‘’
Advanced Enzyme Technologies Ltd
₹293.40
(3.28%)
Tue, 15 Sept 2026, 01:45 am
Consumer Non-Durables
Food: Specialty/Candy
24.5KAdvanced Enzyme Technologies EV/EBITDA Ratio
| Particulars | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49.82 | 26.43 | 18.40 | 12.38 | 26.44 | 26.39 | 24.52 | 29.16 | 23.82 |
| Price to book ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.91 | 4.25 | 3.01 | 1.90 | 3.97 | 2.90 | 2.10 | 2.93 | 2.20 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.88 | 6.13 | 4.95 | 3.62 | 7.71 | 5.97 | 4.79 | 6.24 | 4.91 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43.64 | 21.30 | 16.34 | 11.01 | 23.76 | 25.92 | 17.76 | 25.68 | 20.95 |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4629Cr | 2407Cr | 1970Cr | 1455Cr | 3628Cr | 2867Cr | 2190Cr | 3436Cr | 2618Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30.20 | 14.83 | 10.77 | 7.18 | 15.47 | 13.92 | 13.30 | 16.57 | 13.27 |
| Debt to equity ratio | 1.23 | 0.93 | 0.75 | 1.03 | 2.13 | 1.13 | 1 | 0.54 | 0.37 | 0.12 | 0.12 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 |
| Return on equity % | 0 | 20.24 | 26.86 | 29.97 | 42.40 | 38.26 | 11.93 | 26.87 | 30.95 | 24.67 | 17.67 | 17.94 | 17.03 | 16.12 | 11.61 | 9.09 | 10.42 | 9.55 |
Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio
The Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Advanced Enzyme Technologies Ltd's valuation, profitability, and overall financial performance. Tracking the Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Advanced Enzyme Technologies Ltd (NSE: ADVENZYMES, BSE: 540025) is currently trading at ₹293.40, with a market capitalization of ₹3394.56Cr. As a leading company in the Consumer non-durables sector and Food: specialty/candy industry, monitoring the Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio Current Value
The current Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio stands at 13.27.
The Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 13.27
- 2023: 16.57
- 2022: 13.30
- 2021: 13.92
- 2020: 15.47
The decline in Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Advanced Enzyme Technologies Ltd.
Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Advanced Enzyme Technologies Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.